Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 12/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.42 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1954554 | 1.00 | CHRNA7 (0.51) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL18857738 | 1.00 | CHRNA7 (0.51) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3393862 | 0.84 | CHRNA7 (0.51) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3388664 | 0.84 | CHRNA7 (0.51) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3388669 | 0.84 | CHRNA7 (0.51) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1954551 | 0.83 | CHRNA7 (0.66) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3389709 | 0.83 | CHRNA7 (0.66) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3391748 | 0.83 | CHRNA7 (0.66) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL18857740 | 0.83 | CHRNA7 (0.65) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3390939 | 0.83 | CHRNA7 (0.65) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657010-B2 | Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators | NOVARTIS AG (CH) | 2017-05-23 | — | — | US | claimed |
| US-20140057921-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | claimed |
| EP-1776360-B1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA.7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES. | NOVARTIS AG (CH) | 2010-12-29 | — | — | EP | claimed |
| US-20100093746-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG | 2010-04-15 | — | — | US | claimed |
| US-9657010-B2 | Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators | NOVARTIS AG (CH) | 2017-05-23 | — | — | US | disclosed |
| US-20140057921-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-8609662-B2 | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha. 7-nachr ligands for the treatment of CNS diseases | NOVARTIS AG (CH) | 2013-12-17 | — | — | US | disclosed |
| EP-2457911-A1 | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nAChR ligands for the treatment of CNS diseases. | Novartis AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| EP-1776360-B1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA.7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES. | NOVARTIS AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20100093746-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG | 2010-04-15 | — | — | US | disclosed |
| US-20080194573-A1 | Psychological and neurodegenerative disorders; nicotinic acetylcholine receptors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194573-A1 | Psychological and neurodegenerative disorders; nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA6 | CHRNA7 1/4885CHRNB2 11/4885CHRNA4 8/4885 |
| US-20100093746-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885CHRNB2 11/4885CHRNA4 9/4885 |
| US-20140057921-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885CHRNB2 11/4885CHRNA4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.